Skip to main content

Articles

Page 31 of 38

  1. The hematopoietic syndrome of the acute radiation syndrome (HSARS) is a life-threatening condition in humans exposed to total body irradiation (TBI); no drugs are approved for treating this condition. Recombin...

    Authors: Zoya Gluzman-Poltorak, Sarita R Mendonca, Vladimir Vainstein, Hue Kha and Lena A Basile
    Citation: Journal of Hematology & Oncology 2014 7:31
    Content type: Research Published on:

  2. Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of primary effusion lymphoma (PEL), which represents a rapidly progressing malignancy arising in HIV-infected patients. Conventional chem...

    Authors: Lu Dai, Yueyu Cao, Yihan Chen, Chris Parsons and Zhiqiang Qin
    Citation: Journal of Hematology & Oncology 2014 7:30
    Content type: Research Published on:

  3. A blockade of CD44 is considered a therapeutic option for the elimination of leukemia initiating cells. However, anti-panCD44 can interfere with hematopoiesis. Therefore we explored, whether a CD44 variant iso...

    Authors: Ulrike Erb, Amelie Pajip Megaptche, Xiaoyu Gu, Markus W Büchler and Margot Zöller
    Citation: Journal of Hematology & Oncology 2014 7:29
    Content type: Research Published on:

  4. Cancer stem cells (CSCs) play a key role in the posthepatectomy recurrence of hepatocellular carcinoma (HCC). CD133+ HCC cells exhibit liver CSC–like properties, and CSC differentiation–inducing therapy may lead ...

    Authors: Ke-Zhi Zhang, Qiang-Bo Zhang, Quan-Bao Zhang, Hui-Chuan Sun, Jian-Yang Ao, Zong-Tao Chai, Xiao-Dong Zhu, Lu Lu, Yuan-Yuan Zhang, Yang Bu, Ling-Qun Kong and Zhao-You Tang
    Citation: Journal of Hematology & Oncology 2014 7:28
    Content type: Research Published on:

  5. PNH is associated with abdominal vein thrombosis, which can cause splenomegaly and hypersplenism. The combination of thrombosis, splenomegaly, and thrombocytopenia (TST) is challenging because anticoagulants a...

    Authors: David J Araten, Anna Paola Iori, Karen Brown, Giovanni Fernando Torelli, Walter Barberi, Fiammetta Natalino, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foà and Lucio Luzzatto
    Citation: Journal of Hematology & Oncology 2014 7:27
    Content type: Short report Published on:

  6. The FIP1L1-PDGFRA rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommen...

    Authors: Shilpan Shah, Sanam Loghavi, Guillermo Garcia-Manero and Joseph D Khoury
    Citation: Journal of Hematology & Oncology 2014 7:26
    Content type: Case report Published on:

  7. Myeloproliferative neoplasms (MPNs) are blood malignancies manifested in increased production of red blood cells, white blood cells, and/or platelets. A major molecular lesion associated with the diseases is J...

    Authors: Kaiyao Shi, Wanke Zhao, Yun Chen, Wanting Tina Ho, Ping Yang and Zhizhuang Joe Zhao
    Citation: Journal of Hematology & Oncology 2014 7:25
    Content type: Research Published on:

  8. Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic lar...

    Authors: Nancy L Bartlett, Robert Chen, Michelle A Fanale, Pauline Brice, Ajay Gopal, Scott E Smith, Ranjana Advani, Jeffrey V Matous, Radhakrishnan Ramchandren, Joseph D Rosenblatt, Dirk Huebner, Pamela Levine, Laurie Grove and Andres Forero-Torres
    Citation: Journal of Hematology & Oncology 2014 7:24
    Content type: Research Published on:

  9. 8-chloro-adenosine (8-Cl-Ado) is a unique ribonucleoside analog which is currently in a phase I clinical trial for hematological malignancies. Previously, we demonstrated in breast cancer cells that a 3-day tr...

    Authors: Christine M Stellrecht, Hima V Vangapandu, Xiao-Feng Le, Weiqun Mao and Shujun Shentu
    Citation: Journal of Hematology & Oncology 2014 7:23
    Content type: Research Published on:

  10. AST1306 is an orally active irreversible small molecule inhibitor of EGFR (erbB1), HER2 (erbB2) and HER4 (erbB4) signaling. This is a phase I, open-label, dose-escalation study to evaluate the safety and toler...

    Authors: Jian Zhang, Junning Cao, Jin Li, Yifan Zhang, Zhiyu Chen, Wei Peng, Si Sun, Naiqing Zhao, Jiachen Wang, Dafang Zhong, Xiaofang Zhang and Jing Zhang
    Citation: Journal of Hematology & Oncology 2014 7:22
    Content type: Research Published on:

  11. Cysteine- rich secretory protein 3 (CRISP3) prognostic significance in prostate cancer (PCA) has generated mixed result. Herein, we investigated and independently validated CRISP3 expression in relation to ERG an...

    Authors: Samir Al Bashir, Mohammed Alshalalfa, Samar A Hegazy, Michael Dolph, Bryan Donnelly and Tarek A Bismar
    Citation: Journal of Hematology & Oncology 2014 7:21
    Content type: Research Published on:

  12. Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadju...

    Authors: Mark Thalgott, Thomas Horn, Matthias M Heck, Tobias Maurer, Matthias Eiber, Margitta Retz, Michael Autenrieth, Kathleen Herkommer, Bernd J Krause, Jürgen E Gschwend, Uwe Treiber and Hubert R Kübler
    Citation: Journal of Hematology & Oncology 2014 7:20
    Content type: Research Published on:

  13. Epithelial-to-mesenchymal transition (EMT) and its reverse process, mesenchymal-to-epithelial transition (MET), play important roles in embryogenesis, stem cell biology, and cancer progression. EMT can be regu...

    Authors: Fei Guo, Brittany C Parker Kerrigan, Da Yang, Limei Hu, Ilya Shmulevich, Anil K Sood, Fengxia Xue and Wei Zhang
    Citation: Journal of Hematology & Oncology 2014 7:19
    Content type: Review Published on:

  15. Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) is frequently observed in hematopoietic malignancies. Although PTEN has been implicated in maintaining the quiescence of hematopoietic stem ce...

    Authors: Zhi-Wei Dong, Chun-Guang Ren, Yu Xia, Dan Su, Ting-Ting Du, Hong-Bo Fan, Hao Yuan, Lei Wang, Mei Dong, Wei-Chun Li, Yi Jin, Yi Chen, Min Deng, Ting-Xi Liu, Ai-Hua Gu and Yong Zhou
    Citation: Journal of Hematology & Oncology 2014 7:17
    Content type: Research Published on:

  16. Donor cell engraftment is critical for the success of allogeneic bone marrow transplants. Graft failure is a result of donor cells either failing to engraft initially or being eliminated at later time points. ...

    Authors: Katarzyna A Darlak, Ying Wang, Jian-Ming Li, Wayne AC Harris, Cynthia R Giver, Chunzi Huang and Edmund K Waller
    Citation: Journal of Hematology & Oncology 2014 7:16
    Content type: Research Published on:

  17. Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic ag...

    Authors: Jianping Yuan, Satoshi Kashiwagi, Patrick Reeves, Jean Nezivar, Yuan Yang, Nadiah Hashim Arrifin, Mai Nguyen, Gilberte Jean-Mary, Xiaoyun Tong, Paramjit Uppal, Svetlana Korochkina, Ben Forbes, Tao Chen, Elda Righi, Roderick Bronson, Huabiao Chen…
    Citation: Journal of Hematology & Oncology 2014 7:15
    Content type: Research Published on:

  20. Infantile hemangioma (IH), which is the most common tumor in infants, is a benign vascular neoplasm resulting from the abnormal proliferation of endothelial cells and pericytes. For nearly a century, researche...

    Authors: Yi Ji, Siyuan Chen, Kai Li, Li Li, Chang Xu and Bo Xiang
    Citation: Journal of Hematology & Oncology 2014 7:13
    Content type: Review Published on:

  21. Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphom...

    Authors: Bertrand Coiffier, Barbara Pro, H Miles Prince, Francine Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Martin Wilhelm, Lauren Pinter-Brown, Swaminathan Padmanabhan Iyer, Andrei Shustov, Tina Nielsen, Jean Nichols, Julie Wolfson, Barbara Balser…
    Citation: Journal of Hematology & Oncology 2014 7:11
    Content type: Research Published on:

  22. Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD...

    Authors: Azusa Nagao, Shoko Nakazawa and Hideji Hanabusa
    Citation: Journal of Hematology & Oncology 2014 7:10
    Content type: Case report Published on:

  23. We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further appli...

    Authors: Kunkun Han, Xin Xu, Guodong Chen, Yuanying Zeng, Jingyu Zhu, Xiaolin Du, Zubin Zhang, Biyin Cao, Zhaopeng Liu and Xinliang Mao
    Citation: Journal of Hematology & Oncology 2014 7:9
    Content type: Research Published on:

  24. Oncologic patients who are extreme responders to molecularly targeted therapy provide an important opportunity to better understand the biologic basis of response and, in turn, inform clinical decision making....

    Authors: Vivek Subbiah, Shannon N Westin, Kai Wang, Dejka Araujo, Wei-Lien Wang, Vincent A Miller, Jeffrey S Ross, Phillip J Stephens, Gary A Palmer and Siraj M Ali
    Citation: Journal of Hematology & Oncology 2014 7:8
    Content type: Short report Published on:

  25. Despite encouraging results with the proteasome inhibitor bortezomib in the treatment of hematologic malignancies, emergence of resistance can limit its efficacy, hence calling for novel strategies to overcome...

    Authors: Denise Niewerth, Gertjan JL Kaspers, Yehuda G Assaraf, Johan van Meerloo, Christopher J Kirk, Janet Anderl, Jonathan L Blank, Peter M van de Ven, Sonja Zweegman, Gerrit Jansen and Jacqueline Cloos
    Citation: Journal of Hematology & Oncology 2014 7:7
    Content type: Research Published on:

  26. The purpose of this study was to detect the serum microRNAs (miRNAs) that are differentially expressed in cervical squamous cell carcinoma (SCC) patients and negative controls, with a focus on the miRNA profil...

    Authors: Wen-Tao Wang, Ya-Nan Zhao, Jin-Xing Yan, Mei-Ying Weng, Yan Wang, Yue-Qin Chen and Shun-Jia Hong
    Citation: Journal of Hematology & Oncology 2014 7:6
    Content type: Rapid communication Published on:

  27. The majority of patients with acute myelogenous leukemia (AML) still die of their disease. In order to improve survival rates in AML patients, new strategies are necessary to discover biomarkers for the detect...

    Authors: Mingli Yang, Guohua Jiang, Wenjing Li, Kai Qiu, Min Zhang, Christopher M Carter, Samer Z Al-Quran and Ying Li
    Citation: Journal of Hematology & Oncology 2014 7:5
    Content type: Research Published on:

  28. Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous ...

    Authors: Amy Guillaumet-Adkins, Julia Richter, Maria D Odero, Juan Sandoval, Xabi Agirre, Albert Catala, Manel Esteller, Felipe Prósper, María José Calasanz, Ismael Buño, Mi Kwon, Franck Court, Reiner Siebert and David Monk
    Citation: Journal of Hematology & Oncology 2014 7:4
    Content type: Research Published on:

  29. Because WT1 is expressed in leukemia cells, the development of cancer immunotherapy targeting WT1 has been an attractive translational research topic. However, concern of this therapy still remains, since WT1 ...

    Authors: Hiroaki Asai, Hiroshi Fujiwara, Sohei Kitazawa, Naoto Kobayashi, Toshiki Ochi, Yukihiro Miyazaki, Fumihiro Ochi, Yoshiki Akatsuka, Sachiko Okamoto, Junichi Mineno, Kiyotaka Kuzushima, Hiroaki Ikeda, Hiroshi Shiku and Masaki Yasukawa
    Citation: Journal of Hematology & Oncology 2014 7:3
    Content type: Letter to the Editor Published on:

  31. Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.

    Authors: L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, Adriane M Zernhelt, Daniel M Sullivan, Philippe A Cassier, Eric Chen, Andrea Biondo, Ernestina Tetteh, Lillian L Siu, Amita Patnaik, Kyriakos P Papadopoulos, Johann S de Bono, Anthony W Tolcher and Susan Minton
    Citation: Journal of Hematology & Oncology 2014 7:1
    Content type: Research Published on:

  33. The dismal outcome of malignant peripheral nerve sheath tumor (MPNST) highlights the necessity of finding new therapeutic methods to benefit patients with this aggressive sarcoma. Our purpose was to investigat...

    Authors: Xiaoling Du, Jilong Yang, Antti Ylipää and Ze Zhu
    Citation: Journal of Hematology & Oncology 2013 6:93
    Content type: Research Published on:

  34. MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, muta...

    Authors: Cornel Joseph Phillip, Shadia Zaman, Shujun Shentu, Kumudha Balakrishnan, Jiexin Zhang, Veera Baladandayuthapani, Pietro Taverna, Sanjeev Redkar, Michael Wang, Christine Marie Stellrecht and Varsha Gandhi
    Citation: Journal of Hematology & Oncology 2013 6:92
    Content type: Research Published on:

  36. Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are though...

    Authors: Muhammad Furqan, Akintunde Akinleye, Nikhil Mukhi, Varun Mittal, Yamei Chen and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:90
    Content type: Review Published on:

  37. The chemokine receptor CCR7 mediates lymphoid dissemination of many cancers, including lymphomas and epithelial carcinomas, thus representing an attractive therapeutic target. Previous results have highlighted...

    Authors: Beatriz Somovilla-Crespo, Manuel Alfonso-Pérez, Carlos Cuesta-Mateos, Cristina Carballo-de Dios, Amada E Beltrán, Fernando Terrón, Juan J Pérez-Villar, Carlos Gamallo-Amat, Gema Pérez-Chacón, Elena Fernández-Ruiz, Juan M Zapata and Cecilia Muñoz-Calleja
    Citation: Journal of Hematology & Oncology 2013 6:89
    Content type: Research Published on:

  38. Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-th...

    Authors: Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:88
    Content type: Review Published on:

  39. Recent findings have shown that the blood vessels of different organs exert an active role in regulating organ function. In detail, the endothelium that aligns the vasculature of most organs is fundamental in ...

    Authors: Ana Costa, Joana Afonso, Catarina Osório, Ana L Gomes, Francisco Caiado, Joana Valente, Sandra I Aguiar, Francisco Pinto, Mário Ramirez and Sérgio Dias
    Citation: Journal of Hematology & Oncology 2013 6:87
    Content type: Short report Published on:

  40. The gastrointestinal (GI) tract is one of the most common extranasal sites in extranodal NK/T-cell lymphoma (ENKTL). However, data regarding ENKTL involving the GI tract are relatively scarce. Thus, we perform...

    Authors: Seok Jin Kim, Hyun Ae Jung, Shih-Sung Chuang, Huangming Hong, Cheng-Cheng Guo, Junning Cao, Xiao-Nan Hong, Ritsuro Suzuki, Hye Jin Kang, Jong Ho Won, Wee-Joo Chng, Yok-Lam Kwong, Cheolwon Suh, Yu-Qin Song, Jun Zhu, Kevin Tay…
    Citation: Journal of Hematology & Oncology 2013 6:86
    Content type: Research Published on:

  41. In acute myeloid leukemia (AML), the leukemia initiating cells (LICs) or leukemia stem cells (LSCs) is found within the CD34+CD38- cell compartment. The LICs subpopulation survives chemotherapy and is most probab...

    Authors: Libing Wang, Lei Gao, Sheng Xu, Shenglan Gong, Li Chen, Shuqing Lü, Jie Chen, Huiying Qiu, Xiaoqian Xu, Xiong Ni, Xianmin Song, Weiping Zhang, Jianmin Yang, Min Liu, Xiaoxia Hu and Jianmin Wang
    Citation: Journal of Hematology & Oncology 2013 6:85
    Content type: Short report Published on:

  42. Hematopoietic stem cells (HSCs) are widely used in transplantation therapy to treat a variety of blood diseases. The success of hematopoietic recovery is of high importance and closely related to the patient’s...

    Authors: Wenbin Liao, Jerell R Aguila, Yixin Yao, Jianchang Yang, Gary Zieve, Yongping Jiang, Cecilia Avila, Lisa Senzel, Raymond Lai, Dazhong Xu, Wei Dai and Yupo Ma
    Citation: Journal of Hematology & Oncology 2013 6:84
    Content type: Research Published on:

  43. TP53 defects, i.e. 17p13 deletion and/or nucleotide mutations, associate with short survival and chemorefractoriness in chronic lymphocytic leukemia (CLL). In this context, since direct sequencing of the TP53 gen...

    Authors: Federico Pozzo, Michele Dal Bo, Nadia Peragine, Riccardo Bomben, Antonella Zucchetto, Francesca Maria Rossi, Massimo Degan, Davide Rossi, Annalisa Chiarenza, Alberto Grossi, Francesco Di Raimondo, Francesco Zaja, Gabriele Pozzato, Paola Secchiero, Gianluca Gaidano, Giovanni Del Poeta…
    Citation: Journal of Hematology & Oncology 2013 6:83
    Content type: Research Published on:

  44. T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder and can cooccur in the context of pure red cell aplasia (PRCA). The aim of the current study was to analyze the signal...

    Authors: Zhi-Yuan Qiu, Lei Fan, Li Wang, Chun Qiao, Yu-Jie Wu, Jian-Feng Zhou, Wei Xu and Jian-Yong Li
    Citation: Journal of Hematology & Oncology 2013 6:82
    Content type: Letter to the Editor Published on:

  45. Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available therapy in intermediate-2 or high-risk myelofibrosis patients w...

    Authors: Moshe Talpaz, Ronald Paquette, Lawrence Afrin, Solomon I Hamburg, Josef T Prchal, Katarzyna Jamieson, Howard R Terebelo, Gregory L Ortega, Roger M Lyons, Ramon V Tiu, Elliott F Winton, Kavita Natrajan, Olatoyosi Odenike, David Claxton, Wei Peng, Peter O’Neill…
    Citation: Journal of Hematology & Oncology 2013 6:81
    Content type: Research Published on:

  46. Zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption and has been widely used in bone metastasis malignancies and postmenopausal osteoporosis as a preventive therapy against skeletal-re...

    Authors: Mingfeng He, Weidong Fan and Xianquan Zhang
    Citation: Journal of Hematology & Oncology 2013 6:80
    Content type: Research Published on:

  48. The involvement of protein kinase CK2 in sustaining cancer cell survival could have implications also in the resistance to conventional and unconventional therapies. Moreover, CK2 role in blood tumors is rapid...

    Authors: Laura Quotti Tubi, Carmela Gurrieri, Alessandra Brancalion, Laura Bonaldi, Roberta Bertorelle, Sabrina Manni, Laura Pavan, Federica Lessi, Renato Zambello, Livio Trentin, Fausto Adami, Maria Ruzzene, Lorenzo A Pinna, Gianpietro Semenzato and Francesco Piazza
    Citation: Journal of Hematology & Oncology 2013 6:78
    Content type: Research Published on:

  49. The role of IGF binding protein 2 (IGFBP2) in cancer development is intriguing. Previously we identified IGFBP2 as an extrinsic factor that supports the activity of hematopoietic stem cells (HSCs).

    Authors: Xiaoli Chen, Junke Zheng, Yizhou Zou, Chun Song, Xuemei Hu and Cheng Cheng Zhang
    Citation: Journal of Hematology & Oncology 2013 6:72
    Content type: Research Published on:

  50. Epidermal growth factor receptor- tyrosine kinase inhibitors (EGFR-TKIs) benefit Non-small cell lung cancer (NSCLC) patients, and an EGFR-TKIi erlotinib, is approved for patients with recurrent NSCLC. However,...

    Authors: Aamir Ahmad, Ma’in Y Maitah, Kevin R Ginnebaugh, Yiwei Li, Bin Bao, Shirish M Gadgeel and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2013 6:77
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us